Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NKTCL
MCID: LTH001
MIFTS: 44

Lethal Midline Granuloma (NKTCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Respiratory diseases, Skin diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lethal Midline Granuloma

About this section

MalaCards integrated aliases for Lethal Midline Granuloma:

Name: Lethal Midline Granuloma 12 52 58 15 17 32
Nasal T/natural Killer-Cell Lymphoma 52 58
Extranodal Nasal Nk/t Cell Lymphoma 52 58
Angiocentric T-Cell Lymphoma 52 58
Granuloma, Lethal Midline 43 71
Nk/t-Cell Lymphoma 52 58
Nktcl 52 58
Midfacial Necrotising Lesion 12
Malignant Granuloma of Face 12
Midline Lethal Granuloma 52

Characteristics:

Orphanet epidemiological data:

58
extranodal nasal nk/t cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Blood diseases Respiratory diseases Immune diseases Smell/Taste diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9072
ICD9CM 34 446.3
MeSH 43 D006103
NCIt 49 C8196
SNOMED-CT 67 58961005
ICD10 32 C86 C86.0 M31.2
MESH via Orphanet 44 D054391
ICD10 via Orphanet 33 C86.0
UMLS via Orphanet 72 C0018197 C0392788
Orphanet 58 ORPHA86879
UMLS 71 C0018197
Sources

Summaries for Lethal Midline Granuloma

About this section
NIH Rare Diseases : 52 Extranodal nasal NK/T cell lymphoma (NKTCL) is a rare type of cancer . The term extranodal is used because this form of lymphoma is found outside of the traditional lymph node groupings. It mainly affects men around 50 years of age, and usually arises in the nose, paranasal sinuses (paranasal sinuses are cavities (spaces) or small tunnels. located around or near the nose), orbits or upper airway, and that can present with a nasal mass, nasal bleeding, nasal obstruction, a hole in the palate, and mid-facial and/or upper airway destructive lesions. In advanced disease stages, which are associated with a poor prognosis , NKTCL may affect other organs , but usually without enlarged nodes in the body. The treatment depends on the extent of disease and usually involves radiotherapy and chemotherapy .

MalaCards based summary : Lethal Midline Granuloma, also known as nasal t/natural killer-cell lymphoma, is related to fibrosarcoma of bone and lung lymphoma. An important gene associated with Lethal Midline Granuloma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are NF-kappaB Signaling and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Cisplatin and Aspartic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, nk cells and lymph node.

Wikipedia : 74 Lethal midline granuloma (LMG) is an historical term for a condition in which necrotic and highly... more...

Sources

Related Diseases for Lethal Midline Granuloma

About this section

Diseases related to Lethal Midline Granuloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 fibrosarcoma of bone 30.9 TNFRSF8 SERPINA3
2 lung lymphoma 30.7 TNFRSF8 SPN
3 lymphomatoid granulomatosis 30.5 TIA1 GZMB
4 angioimmunoblastic t-cell lymphoma 30.5 TNFRSF8 TIA1 GZMB
5 orbit lymphoma 30.4 TIA1 NCAM1
6 adult t-cell leukemia 30.4 TNFRSF8 ICAM1 CD7
7 paranasal sinus lymphoma 30.3 TNFRSF8 SCYL1
8 t-cell lymphoma, subcutaneous panniculitis-like 30.2 TNFRSF8 TIA1 GZMB CD7
9 primary cutaneous anaplastic large cell lymphoma 30.2 TIA1 GZMB
10 t-cell lymphoblastic leukemia/lymphoma 30.1 TNFRSF8 ICAM1 CD7
11 cutaneous t cell lymphoma 30.1 TNFRSF8 TIA1 GZMB
12 erythema multiforme 29.9 ICAM1 GZMB
13 anaplastic large cell lymphoma 29.9 TNFRSF8 TIA1 GZMB
14 lymphomatoid papulosis 29.8 TNFRSF8 TIA1 GZMB
15 lymphoma, hodgkin, classic 29.7 TNFRSF8 TIA1 GZMB
16 peripheral t-cell lymphoma 29.6 TNFRSF8 TIA1 NCAM1 GZMB
17 t-cell adult acute lymphocytic leukemia 29.6 TNFRSF8 TIA1 CD7 CD2
18 hepatosplenic t-cell lymphoma 29.6 TIA1 GZMB CD7
19 reticulosarcoma 29.6 TNFRSF8 TIA1 SERPINA3 GZMB
20 aggressive nk-cell leukemia 29.5 TIA1 NCAM1 GZMB CD7 CD2
21 immune deficiency disease 29.5 TNFRSF8 SPN SERPINA3 CD2
22 composite lymphoma 29.4 TNFRSF8 TIA1 SPN GZMB
23 pancytopenia 29.4 SERPINA3 PRF1 NCAM1 CD7 CD2
24 panniculitis 29.3 TNFRSF8 TIA1 NCAM1 GZMB
25 sezary's disease 29.2 TNFRSF8 TIA1 NCAM1 CD7 CD2
26 mycosis fungoides 28.9 TNFRSF8 TIA1 NCAM1 GZMB CD7
27 leukemia, chronic lymphocytic 28.9 TNFRSF8 SPN NCAM1 ICAM1 CD7 CD2
28 nasal cavity lymphoma 28.1 TIA1 SCYL1 PRF1 NCAM1 GZMB CD2
29 lymphoma, non-hodgkin, familial 26.9 TNFRSF8 SPN SERPINA3 PRF1 NCAM1 GZMB
30 neutropenia 10.7
31 lymphoma 10.7
32 cellulitis 10.6
33 rare tumor 10.6
34 splenomegaly 10.5
35 polymorphic reticulosis 10.5
36 47,xyy 10.5
37 enteropathy-associated t-cell lymphoma 10.5
38 allergic hypersensitivity disease 10.4
39 dysphagia 10.4
40 nasopharyngeal carcinoma 10.4
41 graft-versus-host disease 10.4
42 hemophagocytic lymphohistiocytosis 10.4
43 thrombocytopenia 10.4
44 hydroa vacciniforme 10.4
45 leukemia, t-cell, chronic 10.4
46 histiocytosis 10.4
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
48 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
49 crohn's colitis 10.3
50 lymphoblastic lymphoma 10.3

Graphical network of the top 20 diseases related to Lethal Midline Granuloma:



Diseases related to Lethal Midline Granuloma
Sources

Symptoms & Phenotypes for Lethal Midline Granuloma

About this section
Sources

Drugs & Therapeutics for Lethal Midline Granuloma

About this section

Drugs for Lethal Midline Granuloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
2
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
3 N-Methylaspartate Phase 4
4 Antibodies, Blocking Phase 4
5
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
6
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
7
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
8 Orange Approved Phase 3
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Promethazine Approved, Investigational Phase 3 60-87-7 4927
11
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
12
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
13
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
14
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
15
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
16
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
17
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Etoposide Approved Phase 3 33419-42-0 36462
20
Gemcitabine Approved Phase 3 95058-81-4 60750
21
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
24
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
25
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
26
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
27 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
28 Hormones Phase 3
29 Anti-Bacterial Agents Phase 3
30 Neurotransmitter Agents Phase 3
31 Analgesics Phase 3
32 Anesthetics Phase 3
33 Anesthetics, General Phase 3
34 Anesthetics, Intravenous Phase 3
35 Amoxicillin-Potassium Clavulanate Combination Phase 3
36 beta-Lactamase Inhibitors Phase 3
37 Excitatory Amino Acid Antagonists Phase 3
38 Anesthetics, Dissociative Phase 3
39 Muscarinic Agonists Phase 3
40 Cholinergic Agents Phase 3
41 Contraceptives, Oral Phase 3
42 Contraceptive Agents Phase 3
43
Megestrol Phase 3 3562-63-8 19090 3080587
44 Antidepressive Agents Phase 3
45 Hypnotics and Sedatives Phase 3
46 Antidepressive Agents, Tricyclic Phase 3
47 Analgesics, Opioid Phase 3
48 Hematinics Phase 3
49 ferric gluconate Phase 3
50 Iron Supplement Phase 3

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
2 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
3 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Recruiting NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
5 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
8 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
9 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
10 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
11 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
12 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
15 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
16 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
17 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
18 The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
19 A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) Recruiting NCT04365036 Phase 3 Toripalimab;Pegaspargase;Gemcitabine;Oxaliplatin
20 Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies Recruiting NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase
21 PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study Active, not recruiting NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
22 Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study Terminated NCT02359162 Phase 3 Gemcitabine;Oxaliplatin;Pegaspargase;Etoposide;Vincristine;Doxorubicin;Cyclophosphamide;Prednisone
23 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
24 Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma Unknown status NCT00568607 Phase 2 IFO, VP-16, DDP, DXM
25 PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma Unknown status NCT03107962 Phase 2 Pembrolizumab (PD-1 Blocking Antibody)
26 A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma Unknown status NCT01667302 Phase 2 Radiotherapy followed by chemotherapy
27 Phase II Study of L-asparaginase Plus DICE Regimen in Patients With Stage I/II NK/T-cell Lymphoma Unknown status NCT00933673 Phase 2 L-asp, DXM, IFO, VP-16, DDP
28 Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma Unknown status NCT01933282 Phase 2 MESA chemotherapy;MESA
29 Mild-dose Intensity-modulated Radiation Treatment for Stage IE/IIE Extranodal Nasal-type NK/T-cell Lymphoma With Complete Remission Tumor After Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) Chemotherapy:a Phase II Study Unknown status NCT02229682 Phase 2
30 Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) With Concurrent Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma:a Phase II Study Unknown status NCT02080234 Phase 2 GELOX
31 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
32 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
33 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
34 Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics Unknown status NCT02878278 Phase 2 Chidamide BIW;Chidamide QD
35 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
36 A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma Completed NCT00418535 Phase 2 Concurrent Radiotherapy (RT)/cisplatin, VIPD
37 Phase II Study of L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma Completed NCT00854425 Phase 2 L-asparaginase
38 Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Patients With Unfavorable Prognostic Factors: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT02276248 Phase 2 GDP chemotherapy
39 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
40 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01238159 Phase 2
41 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01007526 Phase 2
42 Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma Completed NCT00283985 Phase 2 Kidrolase;Methotrexate;Dexamethasone;Erwinase
43 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
44 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
45 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
46 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
47 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
48 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
49 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
50 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC

Search NIH Clinical Center for Lethal Midline Granuloma

Cochrane evidence based reviews: granuloma, lethal midline

Sources

Genetic Tests for Lethal Midline Granuloma

About this section
Sources

Anatomical Context for Lethal Midline Granuloma

About this section

MalaCards organs/tissues related to Lethal Midline Granuloma:

40
T Cells, Nk Cells, Lymph Node, B Cells, Liver, Skin, Brain
Sources

Publications for Lethal Midline Granuloma

About this section

Articles related to Lethal Midline Granuloma:

(show top 50) (show all 346)
# Title Authors PMID Year
1
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. 61
32296914 2020
2
Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. 61
32333152 2020
3
Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma. 61
32298986 2020
4
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma. 61
32004387 2020
5
Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma. 61
31764026 2020
6
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. 61
32183952 2020
7
Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma. 61
32183945 2020
8
Variants at an HLA and an IL Locus Are Associated with NKTCL. 61
31924702 2020
9
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. 61
31879220 2020
10
Aggressive natural killer/T-cell lymphoma masquerading as acute orbital hemorrhage: a case report. 61
32509082 2020
11
Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma. 61
31441360 2020
12
Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. 61
32127923 2020
13
Oncogenic Network and Hub Genes for Natural Killer/T-Cell Lymphoma Utilizing WGCNA. 61
32195177 2020
14
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. 61
30940492 2020
15
Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma. 61
31724562 2019
16
Lethal Midline Granuloma: An Enigma in Diagnosis-A Rare Case Report. 61
31763310 2019
17
[Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma]. 61
31770855 2019
18
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). 61
31060406 2019
19
Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era. 61
31298062 2019
20
Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience. 61
30971067 2019
21
Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases. 61
31623372 2019
22
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. 61
31527657 2019
23
Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type. 61
30940744 2019
24
c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. 61
30825244 2019
25
Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. 61
31124291 2019
26
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. 61
31001658 2019
27
Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. 61
30546078 2019
28
What we should know about natural killer/T-cell lymphomas. 61
31187536 2019
29
High grade cutaneous B-cell lymphoma presenting as lethal midline granuloma - case report of an unusual presentation. 61
30938452 2019
30
Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. 61
30827933 2019
31
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. 61
30821826 2019
32
The aberrant activation of Wnt pathway caused by β-catenin mutation and its prognostic significance in NK/T-cell lymphoma. 61
30509083 2019
33
FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. 61
30371574 2019
34
Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. 61
30719126 2019
35
MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. 61
30299211 2019
36
Non-coding RNAs in Natural Killer/T-Cell Lymphoma. 61
31263681 2019
37
[Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension]. 61
30678418 2019
38
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). 61
30358175 2018
39
Advances in multiple omics of natural-killer/T cell lymphoma. 61
30514323 2018
40
Comparisons of skin toxicity in patients with extranodal nasal-type natural killer/T-cell lymphoma after treatment with intensity-modulated radiotherapy and conventional radiotherapy. 61
30539832 2018
41
Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). 61
29739712 2018
42
IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma. 61
30340635 2018
43
Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival. 61
30201265 2018
44
IL-13 and IL-13Rα1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation. 61
30107911 2018
45
Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint. 61
30058399 2018
46
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. 61
30241515 2018
47
Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. 61
30102205 2018
48
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. 61
30242098 2018
49
LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). 61
30159126 2018
50
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. 61
29504068 2018
Sources

Variations for Lethal Midline Granuloma

About this section

Cosmic variations for Lethal Midline Granuloma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143390638 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,NK-T cell lymphoma c.394G>A p.E132K 17:7675101-7675101 0
Sources

Expression for Lethal Midline Granuloma

About this section
Search GEO for disease gene expression data for Lethal Midline Granuloma.
Sources

Pathways for Lethal Midline Granuloma

About this section

Pathways related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.97 TNFRSF8 NCAM1 GZMB CD2
2
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.5 SPN NCAM1 CD2
3
Cell adhesion molecules (CAMs) 36
11.09 SPN NCAM1 ICAM1 CD2
4
Innate Lymphoid Cells Differentiation 64
11.03 NCAM1 GZMB CD7
Sources

GO Terms for Lethal Midline Granuloma

About this section

Cellular components related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immunological synapse GO:0001772 8.96 ICAM1 GZMB
2 cell surface GO:0009986 8.92 SPN NCAM1 ICAM1 CD2

Biological processes related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.56 TIA1 PRF1 GZMB CD2
2 leukocyte migration GO:0050900 9.33 SPN ICAM1 CD2
3 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 8.96 TNFRSF8 SPN
4 cytolysis GO:0019835 8.62 PRF1 GZMB

Molecular functions related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 8.8 ICAM1 CD7 CD2
Sources

Sources for Lethal Midline Granuloma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....